Navigation Links
Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
Date:3/18/2009

SAN FRANCISCO, March 18 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has received written permission from the U.S. Food and Drug Administration (FDA) to begin a pivotal Phase 3 trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed docetaxel-based chemotherapy. The placebo-controlled, double-blind, multinational trial will enroll approximately 1,200 patients who will be randomized (2:1) to receive either MDV3100 or placebo. The primary endpoint of the trial will be overall survival.

"This is a significant milestone in the development of this important novel investigational drug," said David T. Hung, M.D., president and chief executive officer of Medivation. "We look forward to starting the trial and rapidly executing a comprehensive Phase 3 development program for MDV3100. Given the encouraging results seen to date in our ongoing Phase 1-2 trial and the limited life expectancy of men with CRPC who have failed chemotherapy, we will work to begin the Phase 3 clinical development of MDV3100 as quickly as possible this year."

The FDA informed the Company that it could test a dose of MDV3100 up to 240mg/day. There are no driving or other restrictions placed on the activities of participants in the trial. Final trial specifics will be announced when the first patient is enrolled.

MDV3100 Ongoing Phase 1-2 Trial

MDV3100 is being evaluated in an ongoing open-label, U.S., Phase 1-2 study of a total of 140 men with CRPC. Patients in this trial were heavily pretreated, with all having failed standard hormonal therapies and many having also failed docetaxel-based chemotherapy. MDV3100 has consistently demonstrated encouraging anti-tumor activity across dose levels and endpoints
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
2. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
5. Medivation Announces Participation in Upcoming Conferences
6. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
7. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
8. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
9. Urban Health Plan Receives $1.3M from Economic Stimulus Package to Increase Health Care Access in Corona, Queens
10. CUREXO Technology Corporation Receives Quality Certificate
11. Silk Information Systemss Silk V 4.2 Receives 08 CCHIT Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... Baja, Mexico (PRWEB) September 20, 2014 ... properties, including Villa del Palmar Cabo San Lucas, Villa ... in relation to Hurricane Odile, with plans to welcome ... October. , As of Sept. 19, all members and ... returned home, thanks to a coordinated effort with government ...
(Date:9/20/2014)... September 21, 2014 Increases in ... to greater waste treatment volumes. However, government regulations ... waste from landfill. According to IBISWorld industry analyst ... implemented strategies aimed at reducing the volume of ... recycled and recovered.” Still, a large proportion of ...
(Date:9/20/2014)... 20, 2014 Ticket Down is ... tickets. This popular ticket exchange is offering their customer ... is nearing that next step in the entertainment business. The ... in the music and entertainment business, but is closing in ... straight No. 1 album, will hit the road next year ...
(Date:9/20/2014)... September 20, 2014 As testosterone ... in federal court, Bernstein Liebhard LLP notes that ... (FDA) have voted overwhelmingly to recommend that prescription ... be subjected to further study in order to ... published on September 18th by Bloomberg.com, the panel ...
(Date:9/20/2014)... Lifeinsurancequoteterm.net has released a new blog post explaining the ... provides for vulnerable family members. , Providing financial ... priority for every provider. It is now possible to ... visiting a doctor. , Life insurance plans that ... to $300,000, but only to healthy applicants. Clients who ...
Breaking Medicine News(10 mins):Health News:Villa Group Resorts in Cabo Largely Unharmed, Plan to Re-open Early October 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2
... Group to Automate and Connect 165 ... Physicians Across 36 Medical Groups, CHICAGO ... leading provider of clinical software, connectivity and,information solutions that physicians ... System (WPAHS) has selected,Allscripts as its Electronic Health Record (EHR) ...
... Sept. 14 A free educational conference,focusing on women ... from Henry Ford Hospital - will take place from ... Troy Marriott, 200 W. Big Beaver Rd. The ... headache,back pain, multiple sclerosis, epilepsy, Parkinson,s disease, dementia and,stroke. ...
... - Article Discussing Analgesic Efficacy of Labopharm,s Once-Daily Tramadol ... in Journal of Pain and Symptom Management -, ... Israel -, LAVAL, QC, Sept. 14 /PRNewswire-FirstCall/ - ... will present a poster discussing the,ability of its once-daily ...
... Global Initiative for Chronic Obstructive Lung Disease (GOLD) ... and prevention of chronic obstructive pulmonary disease (COPD). ... diagnosis, assessment of the diseases severity, and the ... improve treatment of disease. , The GOLD report ...
... 14 Medical Services,International Inc. (Pink Sheets: MSITF) wishes ... the testing of its test kits by the United,States ... kits will,meet any and all testing standards required, as ... world. The Company currently supplies its kits to ...
... Ariz., Sept. 13 Partners Rx Management, LLC,(PRx) is ... Pharmacy,Officer, has been invited to participate in a Panel ... the Fall 2007 Managed Markets,Summit (MMS) presented by Pinsonault ... at the Point Hilton Tapatio Cliffs Hotel --,Phoenix, Arizona. ...
Cached Medicine News:Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 2Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 3Health News:West Penn Allegheny Health System Selects Electronic Health Record From Allscripts 4Health News:Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy 2Health News:Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy 3Health News:Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy 4Health News:Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD 2
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
(Date:9/19/2014)... , Sept. 19, 2014 Merck (NYSE: MRK ... and Canada , is teaming with celebrity ... Diabetes: Logra Tus Metas , an educational program encouraging Hispanics with ... -- a key treatment goal to help reduce the risk of ... are at a higher risk for developing type 2 diabetes ...
(Date:9/19/2014)... Larry J. Merlo , President and CEO of CVS ... National Press Club in Washington, D.C. ... selling tobacco products and its leadership in driving the innovations ... changes in our health care system pose enormous challenges to ... "CVS Health has a truly unique combination of business assets ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... June 04, 2007 /PRNewswire/ -- A nationally renowned,cancer ... a novel study design concept called a Complete ... new agent development.,Studies utilizing this design are currently ... (TOP). TOP,is unique because it conducts early phase ...
... 2007 - Synta,Pharmaceuticals Corp., (NASDAQ: SNTA) a ... small,molecule drugs to treat severe medical conditions, ... at 2:30 p.m. (EST) today to discuss,these ... annual meeting of the,American Society of Clinical ...
Cached Medicine Technology:Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 2Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 3Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 4Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 5
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With reinforced ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: